Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HM-242 is a **novel synthetic antiseptic and disinfectant agent** classified as a triazine derivative with broad-spectrum **microbicidal activity**. It exhibits rapid and potent antimicrobial effects against a wide variety of **Gram-positive and Gram-negative bacteria**, including multidrug-resistant organisms like methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis, as well as yeasts and enveloped viruses (such as influenza and herpes simplex virus)[1][2]. Mechanistically, HM-242 acts primarily on the **cell membrane and cell wall**, causing structural disruption and loss of cell integrity, resulting in rapid microbial killing[2]. It was developed as a new disinfectant, with demonstrated efficacy in vitro and in clinical trials for applications such as **wound cleansing** (e.g., venous leg ulcer)[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HM-242.